A Phase 4 interventional study of Tezepelumab in Asthma, sponsored by AstraZeneca. Completed at 37 sites in United States. Open to participants aged 12 Years to 130 Years. Per ClinicalTrials.gov, last updated 2026-07-16.
Sponsored by AstraZeneca · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 28 studies testing tezepelumab in Asthma — 7 open to participants now, 8 under way, 5 of them phase 3. tezepelumab · Asthma.
Among the 28 studies testing tezepelumab in Asthma, this one is the 10th largest by enrollment, is one of 4 that started in 2022, is one of 2 in phase 4, and was the 17th registered.
4,848 studies on the registry are indexed under Asthma; 605 are open to participants now.
Browse Asthma studies →7 of the 28 studies testing tezepelumab in Asthma are open now, in 12 countries. Recruiting first, the newest first:
University of Alberta · Sites in Canada
Ages 18–55
AstraZeneca · Sites in China
Ages 12–80
AstraZeneca · Sites in United States, Argentina, Brazil and 19 more countries
Ages 5–11
Qianfoshan Hospital · Sites in China
Ages 18–75
Qilu Pharmaceutical Co., Ltd.
Ages 18–80
By country, each count listing its studies:
tezepelumab: first FDA approval 2021 (TEZSPIRE), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →
Of the 417 Asthma studies recruiting now, 140 (34%) set no upper age limit and 205 (49%) stop at 75 or younger; 147 take children under 18; 105 take healthy volunteers.
This study: 12 Years to 130 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
28 studies; the count open now beside each. This study's row is marked.
First in 2011; this study’s year is marked. 4 started in 2022.
This study's enrollment of 286 is above the median of 79 across 3,344 interventional studies indexed under Asthma.
Median enrollment 121 across the 28 interventional studies. Of the 19 that completed or were terminated, 15 (79%) have results posted.
This tab as a report to print or save as PDF → With an account.
20 of 28 have an industry lead sponsor. The 10 most frequent:
AstraZeneca is the lead sponsor of 3,504 studies on the registry; 274 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
359 studies in Asthma by AstraZeneca: 19 open now, 28 under way, 8 of them phase 3. Of 330 finished, 129 (39%) have results posted.
Among the 359 studies in Asthma by AstraZeneca, this one is the 103rd largest by enrollment of the 248 interventional ones that give a count, is one of 13 that started in 2022, is one of 23 in phase 4, and was the 291st registered.
AstraZeneca’s Asthma studies by the year they started, since 1996.
3 of the studies testing tezepelumab in Asthma that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06473779Phase 3AstraZenecaOpen-label Study to Assess Reduction of Background Asthma Medication While Sustaining Asthma Control and Clinical Remission With Tezepelumab in Patients 12-80yrs With Severe Asthma. | 2027-06-25 |
| NCT06705764University of AlbertaTezepelumab in the Treatment of Emergency Room Asthma in Adults (TERAA) | 2026-11 |
| NCT07757841Qianfoshan HospitalReal-World Effectiveness of Tezepelumab in Allergic Bronchopulmonary Aspergillosis | 2027-06-30 |
Add all 3 to your calendar (.ics) → With an account.
Among the 28 studies testing tezepelumab in Asthma, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among AstraZeneca’s 359 in Asthma:
This tab as a report to print or save as PDF → With an account.
To asses effectiveness and safety of tezepelumab in adult and adolescent participants with severe asthma including several under-studied populations in the United States.
This is a multicenter, single-arm, open-label, Post-authorization, Phase 4 study to assess the effectiveness of tezepelumab in the United States (US) among a real-world population of adults and adolescent participants with asthma requiring medium-dose to high-dose inhaled corticosteroids (ICS), with additional controller(s) for at least 12 months with documented history of at least 2 asthma exacerbations during the year prior to enrolment. The total duration of the study for each participant will be approximately 56 weeks. Approximately 400 participants will be enrolled. Participants will receive tezepelumab via subcutaneous injection at the study site, over a 48-week treatment period. The study also includes a post-dosing follow-up period from Weeks 48 to 52.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will be receiving 210 mg of tezepelumab every 4 weeks (Q4W) from Week 0 until Week 48.
Drug: Tezepelumab
Participants will be receiving subcutaneous injection of tezepelumab.
Also known as: AMG 157 or MEDI9929
Annualized Asthma Exacerbation Rate (AAER)
Asthma exacerbations were defined by worsening of asthma symptoms that leads to temporary bolus/burst of systemic corticosteroids for at least 3 consecutive days, or an emergency department (ED) or urgent care visit due to asthma that required systemic corticosteroid (SCS), and/or inpatient hospitalization (≥24 hours) due to asthma. The AAER was based on exacerbations reported by the investigator over 52 weeks. The exacerbation rate was compared between the 12-month period before \[baseline period (BP)\] and the 12-month period after initiation of tezepelumab \[up to study Week 52 (Visit 15) = study period (SP)\].
Time frame: Baseline period (Week -52 to Week 0), Study period (Week 0 to Week 52)
Number of Participants With Asthma Exacerbations
The number of participants with at least one asthma exacerbation in the 12-month period before (baseline period) and after initiation of tezepelumab (study period) (up to study Week 52 = study period) were assessed.
Time frame: Baseline period (Week -52 to Week 0), Study period (Week 0 to Week 52)
Number of Participants Who Completed the 52 -Week Study Period With Any Reduction in Total Number of Asthma Exacerbations
The number of participants who completed the 52 -week study period following tezepelumab initiation with at least 50% reduction, and 100% reduction in total number of asthma exacerbations were assessed.
Time frame: From Baseline period (Week -52 to Week 0) to Study period (Week 0 to Week 52)
Cumulative Asthma Exacerbation Days
The cumulative asthma exacerbation days over 52 weeks before (baseline period) and after initiation of tezepelumab (study period) was assessed.
Time frame: Baseline period (Week -52 to Week 0), Study period (Week 0 to Week 52)
Time to First Asthma Exacerbation
The time to first exacerbation after initiation of tezepelumab was assessed. Data for median time to event have been presented for this endpoint. The median is the descriptive statistics median calculated using a subset of Participants with an event.
Time frame: Baseline (Week 0) to Week 24 (Visit 8 = 6 months) and Week 52 (Visit 15 = 12 months)
Rate of Asthma Exacerbations Associated With Hospitalizations
The rate of asthma exacerbations associated with hospitalization over 52 weeks before (baseline period) and after initiation of tezepelumab (study period) was assessed.
Time frame: Baseline period (Week -52 to Week 0), Study period (Week 0 to Week 52)
Rate of Asthma Exacerbations Associated With Emergency Department /Urgent Care (ED/UC) Visits
The rate of asthma exacerbations associated with ED/UC visits over 52 weeks before (baseline period) and after initiation of tezepelumab (study period) was assessed.
Time frame: Baseline period (Week -52 to Week 0), Study period (Week 0 to Week 52)
Rate of Asthma Exacerbations Associated With Hospitalizations or ED/UC Visits
The rate of asthma exacerbations associated with hospitalizations or ED/UC visits over 52 weeks before (baseline period) and after initiation of tezepelumab (study period) was assessed.
Time frame: Baseline period (Week -52 to Week 0), Study period (Week 0 to Week 52)
Number of Participants With Asthma Exacerbations Associated With Hospitalizations or ED/UC Visits
The number of participants with asthma exacerbations associated with hospitalizations or ED/UC visits in in the 12-month periods before (baseline period) and after initiation of tezepelumab (study period) (up to study Week 52 = study period) were assessed.
Time frame: Baseline period (Week -52 to Week 0), Study period (Week 0 to Week 52)
Cumulative Asthma Exacerbation Days Associated With Hospitalizations or ED/UC Visits
The cumulative asthma exacerbation days associated with hospitalizations or ED/UC over 52 weeks before (baseline period) and after initiation of tezepelumab (study period) were assessed. Total days of exacerbations resulting in hospitalizations or ED/UC visits have been presented.
Time frame: Baseline period (Week -52 to Week 0), Study period (Week 0 to Week 52)
Pre-bronchodilator (Pre-BD) Forced Expiratory Volume in 1 Second (FEV1)
Lung function (FEV1) was measured pre-bronchodilator (pre-BD) by spirometry test. FEV1 is defined as the volume of air exhaled from the lungs in the first second of a forced expiration.
Time frame: Baseline (Week 0), Week 24 (Visit 8 = 6 months), Week 52 (Visit 15 = 12 months)
Change From Baseline in Pre-bronchodilator FEV1
Change from baseline in pre-bronchodilator FEV1 was assessed after initiation of tezepelumab. FEV1 is defined as the volume of air exhaled from the lungs in the first second of a forced expiration.
Time frame: Baseline (Week 0) to Week 24 (Visit 8 = 6 months) and Week 52 (Visit 15 = 12 months)
Number of Pre-BD FEV1 Responders
Number of pre-BD FEV1 responders was defined as participants who achieved either at least 5% or 100 mL improvement from baseline.
Time frame: Week 24 (Visit 8 = 6 months), Week 52 (Visit 15 = 12 months)
Asthma Control Questionnaire (ACQ-6)
The Asthma Control Questionnaire-6 (ACQ-6) is a shortened version of the ACQ that assesses the adequacy of asthma control and change in asthma control which occurs spontaneously or as a result of treatment. ACQ assesses symptoms and rescue bronchodilator use. Questions are weighted equally and scored from 0 (totally controlled) to 6 (severely uncontrolled), with higher scores indicating worse asthma control. The mean (average) ACQ-6 score is the mean of the responses.
Time frame: Baseline (Week 0), Week 24 (Visit 8 = 6 months), Week 52 (Visit 15 = 12 months)
Asthma Impairment and Risk Questionnaire (AIRQ)
The Asthma Impairment and Risk Questionnaire (AIRQ) is a Patient Reported Outcome (PRO) tool intended to identify participants 12 years and older whose health may be at risk because of uncontrolled asthma. It has 10 questions that ask about respiratory symptoms, activity limitation, sleep, rescue medication use, social activities, exercise, difficulty controlling asthma, and exacerbations. All items have a yes/no response option and the tool is scored by summing the total number of 'yes' responses. This sum score is used to assess level of asthma control, ranging from 0 to 10, with higher scores indicating worse asthma control, where: 0-1 is well controlled, 2-4 is not well controlled, and 5-10 is very poorly controlled.
Time frame: Baseline (Week 0), Week 24 (Visit 8 = 6 months), Week 52 (Visit 15 = 12 months)
St. George's Respiratory Questionnaire (SGRQ)
St. George's Respiratory Questionnaire (SGRQ) is a 50-item Patient Reported Outcome (PRO) instrument used to measure health status of participants with airway obstruction diseases. Questionnaire has 2 parts: part 1 consists of 8 items pertaining to severity of respiratory symptoms in preceding 4 weeks; part 2 consists of 42 items related to daily activity and psychosocial impacts of individual's respiratory condition. SGRQ yields a total score and 3 components scores (symptoms, activity, and impacts). Total score indicates impact of disease on overall health status, and it is expressed as percentage of overall impairment, in which 100 represents worst possible health status and 0 indicates best possible health status. Likewise, domain scores range from 0 to 100, with higher scores indicative of greater impairment.
Time frame: Baseline (Week 0), Week 24 (Visit 8 = 6 months), Week 52 (Visit 15 = 12 months)
Change From Baseline in ACQ-6 Score
Change from baseline in Asthma Control Questionnaire-6 (ACQ-6) score was assessed. The ACQ-6 is a shortened version of the ACQ that assesses the adequacy of asthma control and change in asthma control which occurs spontaneously or as a result of treatment. ACQ assesses symptoms and rescue bronchodilator use. Questions are weighted equally and scored from 0 (totally controlled) to 6 (severely uncontrolled), with higher scores indicating worse asthma control.
Time frame: Baseline (Week 0) to Week 24 (Visit 8 = 6 months) and Week 52 (Visit 15 = 12 months)
Change From Baseline in AIRQ Score
Change from baseline in Asthma Impairment and Risk Questionnaire (AIRQ) score was assessed. AIRQ is a Patient Reported Outcome (PRO) tool intended to identify participants 12 years and older whose health may be at risk because of uncontrolled asthma. It has 10 questions that ask about respiratory symptoms, activity limitation, sleep, rescue medication use, social activities, exercise, difficulty controlling asthma, and exacerbations. All items have a yes/no response option and the tool is scored by summing the total number of 'yes' responses. This sum score is used to assess level of asthma control, ranging from 0 to 10, with higher scores indicating worse asthma control, where: 0-1 is well controlled, 2-4 is not well controlled, and 5-10 is very poorly controlled.
Time frame: Baseline (Week 0) to Week 24 (Visit 8 = 6 months) and Week 52 (Visit 15 = 12 months)
Change From Baseline in SGRQ Score
Change from baseline in St. George's Respiratory Questionnaire (SGRQ) score was assessed. SGRQ is a 50-item Patient Reported Outcome (PRO) instrument used to measure health status of participants with airway obstruction diseases. Questionnaire has 2 parts: part 1 consists of 8 items pertaining to severity of respiratory symptoms in preceding 4 weeks; part 2 consists of 42 items related to daily activity and psychosocial impacts of individual's respiratory condition. SGRQ yields a total score and 3 components scores (symptoms, activity, and impacts). Total score indicates impact of disease on overall health status, and it is expressed as percentage of overall impairment, in which 100 represents worst possible health status and 0 indicates best possible health status. Likewise, domain scores range from 0 to 100, with higher scores indicative of greater impairment.
Time frame: Baseline (Week 0) to Week 24 (Visit 8 = 6 months) and Week 52 (Visit 15 = 12 months)
Number of ACQ-6 Responders
Number of ACQ-6 responders were assessed. Individual changes from baseline of ≥ 0.5 were considered to be clinically meaningful (minimum clinically important difference \[MCID\]). ACQ-6 responders in this study were defined as participants who achieved ≥ 1 MCID.
Time frame: Week 24 (Visit 8 = 6 months), Week 52 (Visit 15 = 12 months)
Number of AIRQ Responders
Number of AIRQ responders were assessed. Individual changes from baseline of ≥ 2 were considered to be clinically meaningful (MCID). AIRQ responders in this study were defined as participants who achieved ≥ 1 MCID.
Time frame: Week 24 (Visit 8 = 6 months), Week 52 (Visit 15 = 12 months)
Number of SGRQ Responders
Number of SGRQ responders were assessed. Individual changes from baseline of ≥ 4 were considered to be clinically meaningful (MCID). SGRQ (total and component score) responders in this study were defined as participants who achieved ≥ 1 MCID.
Time frame: Week 24 (Visit 8 = 6 months), Week 52 (Visit 15 = 12 months)
Number of Participants Who Require Any Systemic Corticosteroid (SCS) Use
Number of participants who require any SCS use in the 12-month periods before (baseline period) and after initiation of tezepelumab (up to study Week 52 = study period) were assessed.
Time frame: Baseline period (Week -52 to Week 0), Study period (Week 0 to Week 52)
Cumulative Annualized SCS Dose
Cumulative annualized SCS dose in the 12-month periods before (baseline period) and after initiation of tezepelumab (up to study Week 52 = study period) were assessed. Cumulative annualized SCS dose for each participant was calculated as followed: Cumulative annualized SCS dose = \[sum of (cumulative SCS dose)/length of the planned treatment period\]\*365.25
Time frame: Baseline period (Week -52 to Week 0), Study period (Week 0 to Week 52)
Number of Participants Who Require Longer-term (>30 Consecutive Days) SCS Use
Number of participants who require longer-term (\>30 consecutive days) SCS use in the 12-month periods before (baseline period) and after initiation of tezepelumab (up to study Week 52 = study period) were assessed.
Time frame: Baseline period (Week -52 to Week 0), Study period (Week 0 to Week 52)
Number and Type of Asthma-related Healthcare Resource Utilization (HRU)
Number of participants with specific type of asthma-related HRU in the 12-month period before (baseline period) and after initiation of tezepelumab (up to study Week 52 = study period) were assessed.
Time frame: Baseline period (Week -52 to Week 0), Study period (Week 0 to Week 52)
Duration of Asthma-related Hospitalizations
Duration of asthma-related hospitalization in the 12-month period before (baseline period) and after initiation of tezepelumab (up to study Week 52 = study period) was assessed.
Time frame: Baseline period (Week -52 to Week 0), Study period (Week 0 to Week 52)
AAER for Asthma Exacerbations (Subgroups of Participants)
AAER based on asthma exacerbations in the 12-month period before \[baseline period (BP)\] and after initiation of tezepelumab \[up to study Week 52 = study period (SP)\] was assessed in following subgroups of participants: Blood eosinophil count (BEC) ≥300 cells/microliter; BEC \<300 cells/microliter; With clinically-relevant allergy to perennial aeroallergen; Without clinically-relevant allergy to a perennial aeroallergen; Participants who identify as Black/African American; Adolescents (12-17 years); Comorbid diagnosis of mild to moderate chronic obstructive pulmonary disease (COPD); Significant smoking history (≥10 pack-years of smoking).
Time frame: Baseline period (Week -52 to Week 0), Study period (Week 0 to Week 52)
Number of Participants With Asthma Exacerbations (Subgroups of Participants)
The number of participants with at least one asthma exacerbations in the 12-month period before \[baseline period (BP)\] and after initiation of tezepelumab \[up to study Week 52 = study period (SP)\] were assessed in the following subgroups of participants: BEC ≥300 cells/microliter; BEC \<300 cells/microliter; With a clinically-relevant allergy to a perennial aeroallergen; Without a clinically-relevant allergy to a perennial aeroallergen; Participants who identify as Black/African American; Adolescents (12-17 years); Comorbid diagnosis of mild to moderate COPD; Significant smoking history (≥10 pack-years of smoking).
Time frame: Baseline period (Week -52 to Week 0), Study period (Week 0 to Week 52)
Number of Participants Who Completed the 52-week Study With Any Reduction in Total Number of Asthma Exacerbations (Subgroups of Participants)
The number of participants who completed the 52-week study period following tezepelumab initiation with at least 50% reduction, and 100% reduction in total number of asthma exacerbations were assessed in the following subgroups of participants: BEC ≥300 cells/microliter; BEC \<300 cells/microliter; With a clinically-relevant allergy to a perennial aeroallergen; Without a clinically-relevant allergy to a perennial aeroallergen; Participants who identify as Black/African American; Adolescents (12-17 years); Comorbid diagnosis of mild to moderate COPD; Significant smoking history (≥10 pack-years of smoking).
Time frame: From Baseline period (Week -52 to Week 0) to Study period (Week 0 to Week 52)
Cumulative Asthma Exacerbation Days (Subgroups of Participants)
The cumulative asthma exacerbation days over 52 weeks before \[baseline period (BP)\] and after initiation of tezepelumab \[study period (SP)\] were assessed in the following subgroups of participants: BEC ≥300 cells/microliter; BEC \<300 cells/microliter; With a clinically-relevant allergy to a perennial aeroallergen; Without a clinically-relevant allergy to a perennial aeroallergen; Participants who identify as Black/African American; Adolescents (12-17 years); Comorbid diagnosis of mild to moderate COPD; Significant smoking history (≥10 pack-years of smoking).
Time frame: Baseline period (Week -52 to Week 0), Study period (Week 0 to Week 52)
Rate of Asthma Exacerbations Associated With Hospitalizations (Subgroups of Participants)
Rate of asthma exacerbations associated with hospitalization over 52 weeks before \[baseline period (BP)\] and after initiation of tezepelumab \[study period (SP)\] was assessed in the following subgroups of participants: BEC ≥300 cells/µL; BEC \<300 cells/µL; With a clinically-relevant allergy to perennial aeroallergen; Without a clinically-relevant allergy to perennial aeroallergen; Participants who identify as Black/African American; Adolescents (12-17 years); Comorbid diagnosis of mild to moderate COPD; Significant smoking history (≥10 pack-years of smoking).
Time frame: Baseline period (Week -52 to Week 0), Study period (Week 0 to Week 52)
Rate of Asthma Exacerbations Associated With Emergency Department/Urgent Care (ED/UC) Visits (Subgroups of Participants)
Rate of asthma exacerbations associated with ED/UC visits over 52 weeks before \[baseline period (BP)\] and after initiation of tezepelumab \[study period (SP)\] was assessed in following subgroups of participants: BEC ≥300 cells/µL; BEC \<300 cells/µL; With a clinically-relevant allergy to perennial aeroallergen; Without a clinically-relevant allergy to perennial aeroallergen; Participants who identify as Black/African American; Adolescents (12-17 years); Comorbid diagnosis of mild to moderate COPD; Significant smoking history (≥10 pack-years of smoking).
Time frame: Baseline period (Week -52 to Week 0), Study period (Week 0 to Week 52)
Rate of Asthma Exacerbations Associated With Hospitalizations or ED/UC Visits (Subgroups of Participants)
Rate of asthma exacerbations associated with hospitalizations or ED/UC visits over 52 weeks before \[baseline period (BP)\] and after initiation of tezepelumab \[study period (SP)\] was assessed in following subgroups of participants: BEC ≥300 cells/µL; BEC \<300 cells/µL; With clinically-relevant allergy to perennial aeroallergen; Without clinically-relevant allergy to perennial aeroallergen; Participants who identify as Black/African American; Adolescents (12-17 years); Comorbid diagnosis of mild to moderate COPD; Significant smoking history (≥10 pack-years of smoking).
Time frame: Baseline period (Week -52 to Week 0), Study period (Week 0 to Week 52)
Number and Type of Asthma-related HRU (Subgroups of Participants)
Number of participants with specific type of asthma related HRU in the 12-month period before \[baseline period (BP)\] and after initiation of tezepelumab \[up to study Week 52 = study period (SP)\] were assessed in the following subgroups of participants: BEC ≥300 cells/microliter; BEC \<300 cells/microliter; With a clinically-relevant allergy to a perennial aeroallergen; Without a clinically-relevant allergy to a perennial aeroallergen; Participants who identify as Black/African American; Adolescents (12-17 years); Comorbid diagnosis of mild to moderate COPD; Significant smoking history (≥10 pack-years of smoking). FEIA = Fluorescent enzyme immunoassay
Time frame: Baseline period (Week -52 to Week 0), Study period (Week 0 to Week 52)
Duration of Asthma-related Hospitalizations (Subgroups of Participants)
Duration of asthma-related hospitalization in 12-month period before \[baseline period (BP)\] and after initiation of tezepelumab \[up to study Week 52 = study period (SP)\] was assessed in following subgroups of participants: BEC≥300 cells/µL; BEC\<300 cells/µL; With clinically-relevant allergy to perennial aeroallergen; Without clinically-relevant allergy to perennial aeroallergen; Participants who identify as Black/African American; Adolescents (12-17 years); Comorbid diagnosis of mild to moderate COPD; Significant smoking history (≥10 pack-years of smoking).
Time frame: Baseline period (Week -52 to Week 0), Study period (Week 0 to Week 52)
Number of Participants With Serious Adverse Events (SAEs), Adverse Events That Lead to Tezepelumab Treatment Discontinuation (DAEs), and Adverse Events of Special Interest (AESIs)
The safety and tolerability of tezepelumab were assessed. Data for adverse events on-treatment period have been presented.
Time frame: Up to Week 52
The study was conducted from 29 April 2022 (first participant first visit) to 01 October 2025 (last participant last visit) at 32 study sites in the United States of America (USA).
| Milestone | Tezepelumab |
|---|---|
| Started | 286 |
| Completed | 255 |
| Not completed | 31 |
| Withdrew: Death | 2 |
| Withdrew: Development of study-specific withdrawal criteria | 2 |
| Withdrew: Lost to follow-up | 6 |
| Withdrew: Other | 5 |
| Withdrew: Withdrawal by subject | 16 |
Asthma exacerbations were defined by worsening of asthma symptoms that leads to temporary bolus/burst of systemic corticosteroids for at least 3 consecutive days, or an emergency department (ED) or urgent care visit due to asthma that required systemic corticosteroid (SCS), and/or inpatient hospitalization (≥24 hours) due to asthma. The AAER was based on exacerbations reported by the investigator over 52 weeks. The exacerbation rate was compared between the 12-month period before \[baseline period (BP)\] and the 12-month period after initiation of tezepelumab \[up to study Week 52 (Visit 15) = study period (SP)\].
| Adjusted rate (exacerbations per year) | Tezepelumab |
|---|---|
| Baseline Period | 2.8783 ± 2.69 |
| Study Period | 0.8665 ± 0.71 |
The number of participants with at least one asthma exacerbation in the 12-month period before (baseline period) and after initiation of tezepelumab (study period) (up to study Week 52 = study period) were assessed.
| Participants | Tezepelumab |
|---|---|
| Baseline Period | 285 |
| Study Period | 120 |
The number of participants who completed the 52 -week study period following tezepelumab initiation with at least 50% reduction, and 100% reduction in total number of asthma exacerbations were assessed.
| Participants | Tezepelumab |
|---|---|
| At least 50% reduction | 209 |
| 100% reduction | 148 |
The cumulative asthma exacerbation days over 52 weeks before (baseline period) and after initiation of tezepelumab (study period) was assessed.
| Days | Tezepelumab |
|---|---|
| Baseline Period | 8855 |
| Study Period | 2326 |
The time to first exacerbation after initiation of tezepelumab was assessed. Data for median time to event have been presented for this endpoint. The median is the descriptive statistics median calculated using a subset of Participants with an event.
| Days | Tezepelumab |
|---|---|
| Visit8 | 61 (NA to NA) |
| Visit15 | 102 (NA to NA) |
The rate of asthma exacerbations associated with hospitalization over 52 weeks before (baseline period) and after initiation of tezepelumab (study period) was assessed.
| Adjusted rate (exacerbations per year) | Tezepelumab |
|---|---|
| Study Period | 0.0364 ± 0.02 |
| Baseline Period | 0.1714 ± 0.12 |
The rate of asthma exacerbations associated with ED/UC visits over 52 weeks before (baseline period) and after initiation of tezepelumab (study period) was assessed.
| Adjusted rate (exacerbations per year) | Tezepelumab |
|---|---|
| Study Period | 0.1568 ± 0.11 |
| Baseline Period | 0.6771 ± 0.55 |
The rate of asthma exacerbations associated with hospitalizations or ED/UC visits over 52 weeks before (baseline period) and after initiation of tezepelumab (study period) was assessed.
| Adjusted rate (exacerbations per year) | Tezepelumab |
|---|---|
| Study Period | 0.1647 ± 0.11 |
| Baseline Period | 0.6807 ± 0.55 |
The number of participants with asthma exacerbations associated with hospitalizations or ED/UC visits in in the 12-month periods before (baseline period) and after initiation of tezepelumab (study period) (up to study Week 52 = study period) were assessed.
| Participants | Tezepelumab |
|---|---|
| Baseline Period | 102 |
| Study Period | 34 |
The cumulative asthma exacerbation days associated with hospitalizations or ED/UC over 52 weeks before (baseline period) and after initiation of tezepelumab (study period) were assessed. Total days of exacerbations resulting in hospitalizations or ED/UC visits have been presented.
| Days | Tezepelumab |
|---|---|
| Baseline Period | 2518 |
| Study Period | 517 |
Lung function (FEV1) was measured pre-bronchodilator (pre-BD) by spirometry test. FEV1 is defined as the volume of air exhaled from the lungs in the first second of a forced expiration.
| Litre (L) | Tezepelumab |
|---|---|
| Baseline | 2.160 ± 0.735 |
| Visit 8 | 2.257 ± 0.776 |
| Visit 15 | 2.281 ± 0.743 |
Change from baseline in pre-bronchodilator FEV1 was assessed after initiation of tezepelumab. FEV1 is defined as the volume of air exhaled from the lungs in the first second of a forced expiration.
| Litre (L) | Tezepelumab |
|---|---|
| Change from baseline: Visit 8 | 0.113 ± 0.361 |
| Change from baseline: Visit 15 | 0.111 ± 0.403 |
Number of pre-BD FEV1 responders was defined as participants who achieved either at least 5% or 100 mL improvement from baseline.
| Participants | Tezepelumab |
|---|---|
| Visit8 | 128 |
| Visit15 | 107 |
The Asthma Control Questionnaire-6 (ACQ-6) is a shortened version of the ACQ that assesses the adequacy of asthma control and change in asthma control which occurs spontaneously or as a result of treatment. ACQ assesses symptoms and rescue bronchodilator use. Questions are weighted equally and scored from 0 (totally controlled) to 6 (severely uncontrolled), with higher scores indicating worse asthma control. The mean (average) ACQ-6 score is the mean of the responses.
| Scores on a scale | Tezepelumab |
|---|---|
| Baseline | 2.3863 ± 1.1588 |
| Visit8 | 1.2971 ± 1.0078 |
| Visit15 | 1.1291 ± 1.0164 |
The Asthma Impairment and Risk Questionnaire (AIRQ) is a Patient Reported Outcome (PRO) tool intended to identify participants 12 years and older whose health may be at risk because of uncontrolled asthma. It has 10 questions that ask about respiratory symptoms, activity limitation, sleep, rescue medication use, social activities, exercise, difficulty controlling asthma, and exacerbations. All items have a yes/no response option and the tool is scored by summing the total number of 'yes' responses. This sum score is used to assess level of asthma control, ranging from 0 to 10, with higher scores indicating worse asthma control, where: 0-1 is well controlled, 2-4 is not well controlled, and 5-10 is very poorly controlled.
| Scores on a scale | Tezepelumab |
|---|---|
| Baseline | 5.1 ± 2.5 |
| Visit8 | 2.3 ± 2.4 |
| Visit15 | 2.2 ± 2.5 |
St. George's Respiratory Questionnaire (SGRQ) is a 50-item Patient Reported Outcome (PRO) instrument used to measure health status of participants with airway obstruction diseases. Questionnaire has 2 parts: part 1 consists of 8 items pertaining to severity of respiratory symptoms in preceding 4 weeks; part 2 consists of 42 items related to daily activity and psychosocial impacts of individual's respiratory condition. SGRQ yields a total score and 3 components scores (symptoms, activity, and impacts). Total score indicates impact of disease on overall health status, and it is expressed as percentage of overall impairment, in which 100 represents worst possible health status and 0 indicates best possible health status. Likewise, domain scores range from 0 to 100, with higher scores indicative of greater impairment.
| Scores on a scale | Tezepelumab |
|---|---|
| Baseline | 52.4219 ± 19.9071 |
| Visit8 | 31.7205 ± 21.3066 |
| Visit15 | 29.9202 ± 22.6859 |
Change from baseline in Asthma Control Questionnaire-6 (ACQ-6) score was assessed. The ACQ-6 is a shortened version of the ACQ that assesses the adequacy of asthma control and change in asthma control which occurs spontaneously or as a result of treatment. ACQ assesses symptoms and rescue bronchodilator use. Questions are weighted equally and scored from 0 (totally controlled) to 6 (severely uncontrolled), with higher scores indicating worse asthma control.
| Scores on a scale | Tezepelumab |
|---|---|
| Visit8 | -1.0944 ± 1.1486 |
| Visit15 | -1.2352 ± 1.2540 |
Change from baseline in Asthma Impairment and Risk Questionnaire (AIRQ) score was assessed. AIRQ is a Patient Reported Outcome (PRO) tool intended to identify participants 12 years and older whose health may be at risk because of uncontrolled asthma. It has 10 questions that ask about respiratory symptoms, activity limitation, sleep, rescue medication use, social activities, exercise, difficulty controlling asthma, and exacerbations. All items have a yes/no response option and the tool is scored by summing the total number of 'yes' responses. This sum score is used to assess level of asthma control, ranging from 0 to 10, with higher scores indicating worse asthma control, where: 0-1 is well controlled, 2-4 is not well controlled, and 5-10 is very poorly controlled.
| Scores on a scale | Tezepelumab |
|---|---|
| Visit8 | -2.9 ± 2.7 |
| Visit15 | -2.9 ± 2.8 |
Change from baseline in St. George's Respiratory Questionnaire (SGRQ) score was assessed. SGRQ is a 50-item Patient Reported Outcome (PRO) instrument used to measure health status of participants with airway obstruction diseases. Questionnaire has 2 parts: part 1 consists of 8 items pertaining to severity of respiratory symptoms in preceding 4 weeks; part 2 consists of 42 items related to daily activity and psychosocial impacts of individual's respiratory condition. SGRQ yields a total score and 3 components scores (symptoms, activity, and impacts). Total score indicates impact of disease on overall health status, and it is expressed as percentage of overall impairment, in which 100 represents worst possible health status and 0 indicates best possible health status. Likewise, domain scores range from 0 to 100, with higher scores indicative of greater impairment.
| Scores on a scale | Tezepelumab |
|---|---|
| Visit8 | -20.9296 ± 19.9668 |
| Visit15 | -22.2776 ± 22.1774 |
Number of ACQ-6 responders were assessed. Individual changes from baseline of ≥ 0.5 were considered to be clinically meaningful (minimum clinically important difference \[MCID\]). ACQ-6 responders in this study were defined as participants who achieved ≥ 1 MCID.
| Participants | Tezepelumab |
|---|---|
| Visit8 | 180 |
| Visit15 | 162 |
Number of AIRQ responders were assessed. Individual changes from baseline of ≥ 2 were considered to be clinically meaningful (MCID). AIRQ responders in this study were defined as participants who achieved ≥ 1 MCID.
| Participants | Tezepelumab |
|---|---|
| Visit8 | 168 |
| Visit15 | 139 |
Number of SGRQ responders were assessed. Individual changes from baseline of ≥ 4 were considered to be clinically meaningful (MCID). SGRQ (total and component score) responders in this study were defined as participants who achieved ≥ 1 MCID.
| Participants | Tezepelumab |
|---|---|
| Visit8 | 207 |
| Visit15 | 175 |
Number of participants who require any SCS use in the 12-month periods before (baseline period) and after initiation of tezepelumab (up to study Week 52 = study period) were assessed.
| Participants | Tezepelumab |
|---|---|
| Baseline Period | 279 |
| Study Period | 129 |
Cumulative annualized SCS dose in the 12-month periods before (baseline period) and after initiation of tezepelumab (up to study Week 52 = study period) were assessed. Cumulative annualized SCS dose for each participant was calculated as followed: Cumulative annualized SCS dose = \[sum of (cumulative SCS dose)/length of the planned treatment period\]\*365.25
| mg/year | Tezepelumab |
|---|---|
| Baseline Period | 3671.704 ± 24494.741 |
| Study Period | 1283.780 ± 3983.790 |
Number of participants who require longer-term (\>30 consecutive days) SCS use in the 12-month periods before (baseline period) and after initiation of tezepelumab (up to study Week 52 = study period) were assessed.
| Participants | Tezepelumab |
|---|---|
| Baseline Period | 22 |
| Study Period | 11 |
Number of participants with specific type of asthma-related HRU in the 12-month period before (baseline period) and after initiation of tezepelumab (up to study Week 52 = study period) were assessed.
| Participants | Tezepelumab |
|---|---|
| Any health-related events Baseline Period | 211 |
| Any health-related events Study Period | 166 |
| Asthma health-related events Baseline Period | 211 |
| Asthma health-related events Study Period | 166 |
| Ambulance transport Baseline Period | 6 |
| Ambulance transport Study Period | 4 |
| Hospitalization intensive care Baseline Period | 11 |
| Hospitalization intensive care Study Period | 2 |
| Hospitalization coronary care Baseline Period | 2 |
| Hospitalization coronary care Study Period | 3 |
| Hospitalization general care Baseline Period | 24 |
| Hospitalization general care Study Period | 22 |
| Urgent care visit Baseline Period | 63 |
| Urgent care visit Study Period | 46 |
| Emergency room visit Baseline Period | 59 |
| Emergency room visit Study Period | 54 |
| Hospital admission or emergency department >24 hours Baseline Period | 35 |
| Hospital admission or emergency department >24 hours Study Period | 28 |
| Visit to specialist Baseline Period | 188 |
| Visit to specialist Study Period | 138 |
| Visit to primary health care physician Baseline Period | 98 |
| Visit to primary health care physician Study Period | 71 |
| Other health care visit Baseline Period | 22 |
| Other health care visit Study Period | 38 |
| Home visit physician Baseline Period | 0 |
| Home visit physician Study Period | 0 |
| Home visit nurse Baseline Period | 2 |
| Home visit nurse Study Period | 2 |
| Home visit other health care Baseline Period | 0 |
| Home visit other health care Study Period | 3 |
| Telephone call physician Baseline Period | 34 |
| Telephone call physician Study Period | 41 |
| Telephone call nurse Baseline Period | 26 |
| Telephone call nurse Study Period | 25 |
| Telephone call specialist Baseline Period | 66 |
| Telephone call specialist Study Period | 64 |
| Telephone call other physician/health care Baseline Period | 11 |
| Telephone call other physician/health care Study Period | 26 |
| Medical testing spirometry Baseline Period | 124 |
| Medical testing spirometry Study Period | 75 |
| Medical testing advanced pulmonary function test Baseline Period | 35 |
| Medical testing advanced pulmonary function test Study Period | 12 |
| Medical testing plain chest X-ray Baseline Period | 80 |
| Medical testing plain chest X-ray Study Period | 57 |
| Medical testing computed tomography Baseline Period | 48 |
| Medical testing computed tomography Study Period | 39 |
| Medical testing oxygen initiated Baseline Period | 20 |
| Medical testing oxygen initiated Study Period | 10 |
Duration of asthma-related hospitalization in the 12-month period before (baseline period) and after initiation of tezepelumab (up to study Week 52 = study period) was assessed.
| Crude rate (days per year) | Tezepelumab |
|---|---|
| Hospitalization Study Period | 5.7382 |
| Hospitalization Baseline Period | 4.3374 |
| Hospitalization intensive care Study Period | 3.4928 |
| Hospitalization intensive care Baseline Period | 4.9259 |
| Hospitalization general care Study Period | 6.0572 |
| Hospitalization general care Baseline Period | 3.2612 |
AAER based on asthma exacerbations in the 12-month period before \[baseline period (BP)\] and after initiation of tezepelumab \[up to study Week 52 = study period (SP)\] was assessed in following subgroups of participants: Blood eosinophil count (BEC) ≥300 cells/microliter; BEC \<300 cells/microliter; With clinically-relevant allergy to perennial aeroallergen; Without clinically-relevant allergy to a perennial aeroallergen; Participants who identify as Black/African American; Adolescents (12-17 years); Comorbid diagnosis of mild to moderate chronic obstructive pulmonary disease (COPD); Significant smoking history (≥10 pack-years of smoking).
| Adjusted rate (exacerbations per year) | Tezepelumab |
|---|---|
| Baseline BEC: <300 Study Period | 0.9751 (0.76 to 1.25) |
| Baseline BEC: <300 Baseline Period | 2.8092 (2.61 to 3.02) |
| Baseline BEC: ≥300 Study Period | 0.7142 (0.53 to 0.96) |
| Baseline BEC: ≥300 Baseline Period | 2.9865 (2.63 to 3.40) |
| All perennial fluorescent enzyme immunoassay (FEIA) negative Study Period | 1.0585 (0.80 to 1.40) |
| All perennial FEIA negative Baseline Period | 2.8411 (2.57 to 3.14) |
| Any perennial FEIA positive Study Period | 0.7352 (0.57 to 0.95) |
| Any perennial FEIA positive Baseline Period | 2.8939 (2.64 to 3.17) |
| Baseline BEC <300 & with all perennial FEIA negative Study Period | 1.2936 (0.92 to 1.81) |
| Baseline BEC <300 & with all perennial FEIA negative Baseline Period | 2.8269 (2.51 to 3.18) |
| Baseline BEC <300 & with any perennial FEIA positive Study Period | 0.7345 (0.51 to 1.06) |
| Baseline BEC <300 & with any perennial FEIA positive Baseline Period | 2.8020 (2.55 to 3.08) |
| Baseline BEC ≥300 & with all perennial FEIA negative Study Period | 0.7032 (0.45 to 1.10) |
| Baseline BEC ≥300 & with all perennial FEIA negative Baseline Period | 2.8677 (2.41 to 3.41) |
| Baseline BEC ≥300 & with any perennial FEIA positive Study Period | 0.7175 (0.49 to 1.06) |
| Baseline BEC ≥300 & with any perennial FEIA positive Baseline Period | 3.0649 (2.56 to 3.67) |
| Black or African American Study Period | 0.9007 (0.61 to 1.34) |
| Black or African American Baseline Period | 3.2865 (2.81 to 3.85) |
| Adolescents Study Period | 0.6684 (0.34 to 1.30) |
| Adolescents Baseline Period | 2.3218 (1.97 to 2.74) |
| Mild to moderate COPD Study Period | 0.9377 (0.60 to 1.46) |
| Mild to moderate COPD Baseline Period | 2.7046 (2.42 to 3.03) |
| Baseline smoking status Study Period | 1.0363 (0.74 to 1.46) |
| Baseline smoking status Baseline Period | 2.8811 (2.63 to 3.16) |
The number of participants with at least one asthma exacerbations in the 12-month period before \[baseline period (BP)\] and after initiation of tezepelumab \[up to study Week 52 = study period (SP)\] were assessed in the following subgroups of participants: BEC ≥300 cells/microliter; BEC \<300 cells/microliter; With a clinically-relevant allergy to a perennial aeroallergen; Without a clinically-relevant allergy to a perennial aeroallergen; Participants who identify as Black/African American; Adolescents (12-17 years); Comorbid diagnosis of mild to moderate COPD; Significant smoking history (≥10 pack-years of smoking).
| Participants | Tezepelumab |
|---|---|
| Allergic & BEC ≥300 Baseline Period | 75 |
| Allergic & BEC ≥300 Study Period | 30 |
| Non-allergic & BEC ≥300 Baseline Period | 45 |
| Non-allergic & BEC ≥300 Study Period | 19 |
| Allergic & BEC <300 Baseline Period | 89 |
| Allergic & BEC <300 Study Period | 32 |
| Non-allergic & BEC <300 Baseline Period | 74 |
| Non-allergic & BEC <300 Study Period | 37 |
| Black/African American Baseline Period | 63 |
| Black/African American Study Period | 27 |
| Adolescents Baseline Period | 19 |
| Adolescents Study Period | 7 |
| Mild to moderate COPD Baseline Period | 57 |
| Mild to moderate COPD Study Period | 26 |
| Smokers Baseline Period | 83 |
| Smokers Study Period | 38 |
The number of participants who completed the 52-week study period following tezepelumab initiation with at least 50% reduction, and 100% reduction in total number of asthma exacerbations were assessed in the following subgroups of participants: BEC ≥300 cells/microliter; BEC \<300 cells/microliter; With a clinically-relevant allergy to a perennial aeroallergen; Without a clinically-relevant allergy to a perennial aeroallergen; Participants who identify as Black/African American; Adolescents (12-17 years); Comorbid diagnosis of mild to moderate COPD; Significant smoking history (≥10 pack-years of smoking).
| Participants | Tezepelumab |
|---|---|
| Allergic and BEC ≥300 ≥50% reduction | 60 |
| Allergic and BEC ≥300 100% reduction | 40 |
| Non-allergic and BEC ≥300 ≥50% reduction | 36 |
| Non-allergic and BEC ≥300 100% reduction | 26 |
| Allergic and BEC <300 ≥50% reduction | 68 |
| Allergic and BEC <300 100% reduction | 50 |
| Non-allergic and BEC <300 ≥50% reduction | 44 |
| Non-allergic and BEC <300 100% reduction | 32 |
| Black/African American ≥50% reduction | 44 |
| Black/African American 100% reduction | 31 |
| Adolescents ≥50% reduction | 14 |
| Adolescents 100% reduction | 10 |
| Mild to moderate COPD ≥50% reduction | 41 |
| Mild to moderate COPD 100% reduction | 28 |
| Smokers ≥50% reduction | 56 |
| Smokers 100% reduction | 39 |
The cumulative asthma exacerbation days over 52 weeks before \[baseline period (BP)\] and after initiation of tezepelumab \[study period (SP)\] were assessed in the following subgroups of participants: BEC ≥300 cells/microliter; BEC \<300 cells/microliter; With a clinically-relevant allergy to a perennial aeroallergen; Without a clinically-relevant allergy to a perennial aeroallergen; Participants who identify as Black/African American; Adolescents (12-17 years); Comorbid diagnosis of mild to moderate COPD; Significant smoking history (≥10 pack-years of smoking).
| Days | Tezepelumab |
|---|---|
| Allergic and BEC ≥300 Baseline Period | 2539 |
| Allergic and BEC ≥300 Study Period | 478 |
| Non-allergic and BEC ≥300 Baseline Period | 1230 |
| Non-allergic and BEC ≥300 Study Period | 291 |
| Allergic and BEC <300 Baseline Period | 2735 |
| Allergic and BEC <300 Study Period | 727 |
| Non-allergic and BEC <300 Baseline Period | 2322 |
| Non-allergic and BEC <300 Study Period | 806 |
| Black/African American Baseline Period | 1865 |
| Black/African American Study Period | 441 |
| Adolescents Baseline Period | 425 |
| Adolescents Study Period | 73 |
| Mild to moderate COPD Baseline Period | 1679 |
| Mild to moderate COPD Study Period | 554 |
| Smokers Baseline Period | 2384 |
| Smokers Study Period | 837 |
Rate of asthma exacerbations associated with hospitalization over 52 weeks before \[baseline period (BP)\] and after initiation of tezepelumab \[study period (SP)\] was assessed in the following subgroups of participants: BEC ≥300 cells/µL; BEC \<300 cells/µL; With a clinically-relevant allergy to perennial aeroallergen; Without a clinically-relevant allergy to perennial aeroallergen; Participants who identify as Black/African American; Adolescents (12-17 years); Comorbid diagnosis of mild to moderate COPD; Significant smoking history (≥10 pack-years of smoking).
| Crude rate (exacerbations per year) | Tezepelumab |
|---|---|
| Baseline BEC: <300 Study Period | 0.0663 |
| Baseline BEC: <300 Baseline Period | 0.1925 |
| Baseline BEC: ≥300 Study Period | 0.0000 |
| Baseline BEC: ≥300 Baseline Period | 0.1420 |
| All perennial fluorescent enzyme immunoassay (FEIA) negative Study Period | 0.0626 |
| All perennial FEIA negative Baseline Period | 0.1269 |
| Any perennial FEIA positive Study Period | 0.0188 |
| Any perennial FEIA positive Baseline Period | 0.2006 |
| Baseline BEC <300 & with all perennial FEIA negative Study Period | 0.1032 |
| Baseline BEC <300 & with all perennial FEIA negative Baseline Period | 0.1361 |
| Baseline BEC <300 & with any perennial FEIA positive Study Period | 0.0361 |
| Baseline BEC <300 & with any perennial FEIA positive Baseline Period | 0.2399 |
| Baseline BEC ≥300 & with all perennial FEIA negative Study Period | 0.0000 |
| Baseline BEC ≥300 & with all perennial FEIA negative Baseline Period | 0.1118 |
| Baseline BEC ≥300 & with any perennial FEIA positive Study Period | 0.0000 |
| Baseline BEC ≥300 & with any perennial FEIA positive Baseline Period | 0.1600 |
| Black or African American Study Period | 0.0343 |
| Black or African American Baseline Period | 0.4083 |
| Adolescents Study Period | 0.0000 |
| Adolescents Baseline Period | 0.2685 |
| Mild to moderate COPD Study Period | 0.0555 |
| Mild to moderate COPD Baseline Period | 0.1958 |
| Baseline smokers Study Period | 0.0387 |
| Baseline smokers Baseline Period | 0.2195 |
Rate of asthma exacerbations associated with ED/UC visits over 52 weeks before \[baseline period (BP)\] and after initiation of tezepelumab \[study period (SP)\] was assessed in following subgroups of participants: BEC ≥300 cells/µL; BEC \<300 cells/µL; With a clinically-relevant allergy to perennial aeroallergen; Without a clinically-relevant allergy to perennial aeroallergen; Participants who identify as Black/African American; Adolescents (12-17 years); Comorbid diagnosis of mild to moderate COPD; Significant smoking history (≥10 pack-years of smoking).
| Crude rate (exacerbations per year) | Tezepelumab |
|---|---|
| Baseline BEC: <300 Study Period | 0.2205 |
| Baseline BEC: <300 Baseline Period | 0.6567 |
| Baseline BEC: ≥300 Study Period | 0.0679 |
| Baseline BEC: ≥300 Baseline Period | 0.6340 |
| All perennial fluorescent enzyme immunoassay (FEIA) negative Study Period | 0.1800 |
| All perennial FEIA negative Baseline Period | 0.5706 |
| Any perennial FEIA positive Study Period | 0.1390 |
| Any perennial FEIA positive Baseline Period | 0.7007 |
| Baseline BEC <300 & with all perennial FEIA negative Study Period | 0.2224 |
| Baseline BEC <300 & with all perennial FEIA negative Baseline Period | 0.5997 |
| Baseline BEC <300 & with any perennial FEIA positive Study Period | 0.2189 |
| Baseline BEC <300 & with any perennial FEIA positive Baseline Period | 0.7046 |
| Baseline BEC ≥300 & with all perennial FEIA negative Study Period | 0.1144 |
| Baseline BEC ≥300 & with all perennial FEIA negative Baseline Period | 0.5230 |
| Baseline BEC ≥300 & with any perennial FEIA positive Study Period | 0.0405 |
| Baseline BEC ≥300 & with any perennial FEIA positive Baseline Period | 0.7012 |
| Black or African American Study Period | 0.2595 |
| Black or African American Baseline Period | 1.0795 |
| Adolescents Study Period | 0.0000 |
| Adolescents Baseline Period | 0.4866 |
| Mild to moderate COPD Study Period | 0.2049 |
| Mild to moderate COPD Baseline Period | 0.5630 |
| Baseline smokers Study Period | 0.1688 |
| Baseline smokers Baseline Period | 0.6520 |
Rate of asthma exacerbations associated with hospitalizations or ED/UC visits over 52 weeks before \[baseline period (BP)\] and after initiation of tezepelumab \[study period (SP)\] was assessed in following subgroups of participants: BEC ≥300 cells/µL; BEC \<300 cells/µL; With clinically-relevant allergy to perennial aeroallergen; Without clinically-relevant allergy to perennial aeroallergen; Participants who identify as Black/African American; Adolescents (12-17 years); Comorbid diagnosis of mild to moderate COPD; Significant smoking history (≥10 pack-years of smoking).
| Crude rate (exacerbations per year) | Tezepelumab |
|---|---|
| Baseline BEC: <300 Study Period | 0.2339 |
| Baseline BEC: <300 Baseline Period | 0.6632 |
| Baseline BEC: ≥300 Study Period | 0.0679 |
| Baseline BEC: ≥300 Baseline Period | 0.6340 |
| All perennial fluorescent enzyme immunoassay (FEIA) negative Study Period | 0.1981 |
| All perennial FEIA negative Baseline Period | 0.5794 |
| Any perennial FEIA positive Study Period | 0.1390 |
| Any perennial FEIA positive Baseline Period | 0.7007 |
| Baseline BEC <300 & with all perennial FEIA negative Study Period | 0.2524 |
| Baseline BEC <300 & with all perennial FEIA negative Baseline Period | 0.6140 |
| Baseline BEC <300 & with any perennial FEIA positive Study Period | 0.2189 |
| Baseline BEC <300 & with any perennial FEIA positive Baseline Period | 0.7046 |
| Baseline BEC ≥300 & with all perennial FEIA negative Study Period | 0.1144 |
| Baseline BEC ≥300 & with all perennial FEIA negative Baseline Period | 0.5230 |
| Baseline BEC ≥300 & with any perennial FEIA positive Study Period | 0.0405 |
| Baseline BEC ≥300 & with any perennial FEIA positive Baseline Period | 0.7012 |
| Black or African American Study Period | 0.2595 |
| Black or African American Baseline Period | 1.0795 |
| Adolescents Study Period | 0.0000 |
| Adolescents Baseline Period | 0.4866 |
| Mild to moderate COPD Study Period | 0.2236 |
| Mild to moderate COPD Baseline Period | 0.5630 |
| Baseline smokers Study Period | 0.1819 |
| Baseline smokers Baseline Period | 0.6520 |
Number of participants with specific type of asthma related HRU in the 12-month period before \[baseline period (BP)\] and after initiation of tezepelumab \[up to study Week 52 = study period (SP)\] were assessed in the following subgroups of participants: BEC ≥300 cells/microliter; BEC \<300 cells/microliter; With a clinically-relevant allergy to a perennial aeroallergen; Without a clinically-relevant allergy to a perennial aeroallergen; Participants who identify as Black/African American; Adolescents (12-17 years); Comorbid diagnosis of mild to moderate COPD; Significant smoking history (≥10 pack-years of smoking). FEIA = Fluorescent enzyme immunoassay
| Participants | Tezepelumab |
|---|---|
| Baseline BEC<300 Any health-related events Baseline Period | 121 |
| Baseline BEC<300 Any health-related events Study Period | 99 |
| Baseline BEC<300 Asthma health-related events Baseline Period | 121 |
| Baseline BEC<300 Asthma health-related events Study Period | 99 |
| Baseline BEC<300 Ambulance transport Baseline Period | 2 |
| Baseline BEC<300 Ambulance transport Study Period | 4 |
| Baseline BEC<300 Hospitalization intensive care Baseline Period | 7 |
| Baseline BEC<300 Hospitalization intensive care Study Period | 1 |
| Baseline BEC<300 Hospitalization coronary care Baseline Period | 1 |
| Baseline BEC<300 Hospitalization coronary care Study Period | 1 |
| Baseline BEC<300 Hospitalization general care Baseline Period | 14 |
| Baseline BEC<300 Hospitalization general care Study Period | 19 |
| Baseline BEC<300 Urgent care visit Baseline Period | 30 |
| Baseline BEC<300 Urgent care visit Study Period | 29 |
| Baseline BEC<300 Emergency room visit Baseline Period | 33 |
| Baseline BEC<300 Emergency room visit Study Period | 39 |
| Baseline BEC<300 Hospital admission or emergency department >24 hours Baseline Period | 22 |
| Baseline BEC<300 Hospital admission or emergency department >24 hours Study Period | 23 |
| Baseline BEC<300 Visit to specialist Baseline Period | 109 |
| Baseline BEC<300 Visit to specialist Study Period | 81 |
| Baseline BEC<300 Visit to primary health care physician Baseline Period | 54 |
| Baseline BEC<300 Visit to primary health care physician Study Period | 42 |
| Baseline BEC<300 Other health care visit Baseline Period | 13 |
| Baseline BEC<300 Other health care visit Study Period | 27 |
| Baseline BEC<300 Home visit physician Baseline Period | 0 |
| Baseline BEC<300 Home visit physician Study Period | 0 |
| Baseline BEC<300 Home visit nurse Baseline Period | 0 |
| Baseline BEC<300 Home visit nurse Study Period | 1 |
| Baseline BEC<300 Home visit other health care Baseline Period | 0 |
| Baseline BEC<300 Home visit other health care Study Period | 2 |
| Baseline BEC<300 Telephone call physician Baseline Period | 20 |
| Baseline BEC<300 Telephone call physician Study Period | 26 |
| Baseline BEC<300 Telephone call nurse Baseline Period | 14 |
| Baseline BEC<300 Telephone call nurse Study Period | 15 |
| Baseline BEC<300 Telephone call specialist Baseline Period | 35 |
| Baseline BEC<300 Telephone call specialist Study Period | 37 |
| Baseline BEC<300 Telephone call other physician/health care Baseline Period | 6 |
| Baseline BEC<300 Telephone call other physician/health care Study Period | 16 |
| Baseline BEC<300 Medical testing spirometry Baseline Period | 66 |
| Baseline BEC<300 Medical testing spirometry Study Period | 43 |
| Baseline BEC<300 Medical testing advanced pulmonary function test Baseline Period | 17 |
| Baseline BEC<300 Medical testing advanced pulmonary function test Study Period | 9 |
| Baseline BEC<300 Medical testing plain chest X-ray Baseline Period | 48 |
| Baseline BEC<300 Medical testing plain chest X-ray Study Period | 42 |
| Baseline BEC<300 Medical testing computed tomography Baseline Period | 29 |
| Baseline BEC<300 Medical testing computed tomography Study Period | 32 |
| Baseline BEC<300 Medical testing oxygen initiated Baseline Period | 14 |
| Baseline BEC<300 Medical testing oxygen initiated Study Period | 7 |
| Baseline BEC≥300 Any health-related events Baseline Period | 89 |
| Baseline BEC≥300 Any health-related events Study Period | 65 |
| Baseline BEC≥300 Asthma health-related events Baseline Period | 89 |
| Baseline BEC≥300 Asthma health-related events Study Period | 65 |
| Baseline BEC≥300 Ambulance transport Baseline Period | 4 |
| Baseline BEC≥300 Ambulance transport Study Period | 0 |
| Baseline BEC≥300 Hospitalization intensive care Baseline Period | 4 |
| Baseline BEC≥300 Hospitalization intensive care Study Period | 1 |
| Baseline BEC≥300 Hospitalization coronary care Baseline Period | 1 |
| Baseline BEC≥300 Hospitalization coronary care Study Period | 2 |
| Baseline BEC≥300 Hospitalization general care Baseline Period | 10 |
| Baseline BEC≥300 Hospitalization general care Study Period | 3 |
| Baseline BEC≥300 Urgent care visit Baseline Period | 32 |
| Baseline BEC≥300 Urgent care visit Study Period | 16 |
| Baseline BEC≥300 Emergency room visit Baseline Period | 26 |
| Baseline BEC≥300 Emergency room visit Study Period | 15 |
| Baseline BEC≥300 Hospital admission or emergency department >24 hours Baseline Period | 13 |
| Baseline BEC≥300 Hospital admission or emergency department >24 hours Study Period | 5 |
| Baseline BEC≥300 Visit to specialist Baseline Period | 78 |
| Baseline BEC≥300 Visit to specialist Study Period | 55 |
| Baseline BEC≥300 Visit to primary health care physician Baseline Period | 44 |
| Baseline BEC≥300 Visit to primary health care physician Study Period | 28 |
| Baseline BEC≥300 Other health care visit Baseline Period | 9 |
| Baseline BEC≥300 Other health care visit Study Period | 11 |
| Baseline BEC≥300 Home visit physician Baseline Period | 0 |
| Baseline BEC≥300 Home visit physician Study Period | 0 |
| Baseline BEC≥300 Home visit nurse Baseline Period | 2 |
| Baseline BEC≥300 Home visit nurse Study Period | 1 |
| Baseline BEC≥300 Home visit other health care Baseline Period | 0 |
| Baseline BEC≥300 Home visit other health care Study Period | 1 |
| Baseline BEC≥300 Telephone call physician Baseline Period | 14 |
| Baseline BEC≥300 Telephone call physician Study Period | 14 |
| Baseline BEC≥300 Telephone call nurse Baseline Period | 12 |
| Baseline BEC≥300 Telephone call nurse Study Period | 10 |
| Baseline BEC≥300 Telephone call specialist Baseline Period | 31 |
| Baseline BEC≥300 Telephone call specialist Study Period | 25 |
| Baseline BEC≥300 Telephone call other physician/health care Baseline Period | 5 |
| Baseline BEC≥300 Telephone call other physician/health care Study Period | 10 |
| Baseline BEC≥300 Medical testing spirometry Baseline Period | 58 |
| Baseline BEC≥300 Medical testing spirometry Study Period | 31 |
| Baseline BEC≥300 Medical testing advanced pulmonary function test Baseline Period | 18 |
| Baseline BEC≥300 Medical testing advanced pulmonary function test Study Period | 3 |
| Baseline BEC≥300 Medical testing plain chest X-ray Baseline Period | 31 |
| Baseline BEC≥300 Medical testing plain chest X-ray Study Period | 14 |
| Baseline BEC≥300 Medical testing computed tomography Baseline Period | 18 |
| Baseline BEC≥300 Medical testing computed tomography Study Period | 7 |
| Baseline BEC≥300 Medical testing oxygen initiated Baseline Period | 6 |
| Baseline BEC≥300 Medical testing oxygen initiated Study Period | 3 |
| All perennial FEIA negative Any health-related events Baseline Period | 88 |
| All perennial FEIA negative Any health-related events Study Period | 73 |
| All perennial FEIA negative Asthma health-related events Baseline Period | 88 |
| All perennial FEIA negative Asthma health-related events Study Period | 73 |
| All perennial FEIA negative Ambulance transport Baseline Period | 1 |
| All perennial FEIA negative Ambulance transport Study Period | 1 |
| All perennial FEIA negative Hospitalization intensive care Baseline Period | 2 |
| All perennial FEIA negative Hospitalization intensive care Study Period | 0 |
| All perennial FEIA negative Hospitalization coronary care Baseline Period | 0 |
| All perennial FEIA negative Hospitalization coronary care Study Period | 0 |
| All perennial FEIA negative Hospitalization general care Baseline Period | 8 |
| All perennial FEIA negative Hospitalization general care Study Period | 11 |
| All perennial FEIA negative Urgent care visit Baseline Period | 25 |
| All perennial FEIA negative Urgent care visit Study Period | 25 |
| All perennial FEIA negative Emergency room visit Baseline Period | 20 |
| All perennial FEIA negative Emergency room visit Study Period | 24 |
| All perennial FEIA negative Hospital admission or emergency department >24 hours Baseline Period | 11 |
| All perennial FEIA negative Hospital admission or emergency department >24 hours Study Period | 13 |
| All perennial FEIA negative Visit to specialist Baseline Period | 77 |
| All perennial FEIA negative Visit to specialist Study Period | 57 |
| All perennial FEIA negative Visit to primary health care physician Baseline Period | 35 |
| All perennial FEIA negative Visit to primary health care physician Study Period | 36 |
| All perennial FEIA negative Other health care visit Baseline Period | 8 |
| All perennial FEIA negative Other health care visit Study Period | 16 |
| All perennial FEIA negative Home visit physician Baseline Period | 0 |
| All perennial FEIA negative Home visit physician Study Period | 0 |
| All perennial FEIA negative Home visit nurse Baseline Period | 0 |
| All perennial FEIA negative Home visit nurse Study Period | 2 |
| All perennial FEIA negative Home visit other health care Baseline Period | 0 |
| All perennial FEIA negative Home visit other health care Study Period | 2 |
| All perennial FEIA negative Telephone call physician Baseline Period | 15 |
| All perennial FEIA negative Telephone call physician Study Period | 20 |
| All perennial FEIA negative Telephone call nurse Baseline Period | 10 |
| All perennial FEIA negative Telephone call nurse Study Period | 14 |
| All perennial FEIA negative Telephone call specialist Baseline Period | 26 |
| All perennial FEIA negative Telephone call specialist Study Period | 25 |
| All perennial FEIA negative Telephone call other physician/health care Baseline Period | 3 |
| All perennial FEIA negative Telephone call other physician/health care Study Period | 14 |
| All perennial FEIA negative Medical testing spirometry Baseline Period | 41 |
| All perennial FEIA negative Medical testing spirometry Study Period | 27 |
| All perennial FEIA negative Medical testing advanced pulmonary function test Baseline Period | 13 |
| All perennial FEIA negative Medical testing advanced pulmonary function test Study Period | 7 |
| All perennial FEIA negative Medical testing plain chest X-ray Baseline Period | 28 |
| All perennial FEIA negative Medical testing plain chest X-ray Study Period | 28 |
| All perennial FEIA negative Medical testing computed tomography Baseline Period | 26 |
| All perennial FEIA negative Medical testing computed tomography Study Period | 24 |
| All perennial FEIA negative Medical testing oxygen initiated Baseline Period | 4 |
| All perennial FEIA negative Medical testing oxygen initiated Study Period | 2 |
| Any perennial FEIA positive Any health-related events Baseline Period | 123 |
| Any perennial FEIA positive Any health-related events Study Period | 93 |
| Any perennial FEIA positive Asthma health-related events Baseline Period | 123 |
| Any perennial FEIA positive Asthma health-related events Study Period | 93 |
| Any perennial FEIA positive Ambulance transport Baseline Period | 5 |
| Any perennial FEIA positive Ambulance transport Study Period | 3 |
| Any perennial FEIA positive Hospitalization intensive care Baseline Period | 9 |
| Any perennial FEIA positive Hospitalization intensive care Study Period | 2 |
| Any perennial FEIA positive Hospitalization coronary care Baseline Period | 2 |
| Any perennial FEIA positive Hospitalization coronary care Study Period | 3 |
| Any perennial FEIA positive Hospitalization general care Baseline Period | 16 |
| Any perennial FEIA positive Hospitalization general care Study Period | 11 |
| Any perennial FEIA positive Urgent care visit Baseline Period | 38 |
| Any perennial FEIA positive Urgent care visit Study Period | 21 |
| Any perennial FEIA positive Emergency room visit Baseline Period | 39 |
| Any perennial FEIA positive Emergency room visit Study Period | 30 |
| Any perennial FEIA positive Hospital admission or emergency department >24 hours Baseline Period | 24 |
| Any perennial FEIA positive Hospital admission or emergency department >24 hours Study Period | 15 |
| Any perennial FEIA positive Visit to specialist Baseline Period | 111 |
| Any perennial FEIA positive Visit to specialist Study Period | 81 |
| Any perennial FEIA positive Visit to primary health care physician Baseline Period | 63 |
| Any perennial FEIA positive Visit to primary health care physician Study Period | 35 |
| Any perennial FEIA positive Other health care visit Baseline Period | 14 |
| Any perennial FEIA positive Other health care visit Study Period | 22 |
| Any perennial FEIA positive Home visit physician Baseline Period | 0 |
| Any perennial FEIA positive Home visit physician Study Period | 0 |
| Any perennial FEIA positive Home visit nurse Baseline Period | 2 |
| Any perennial FEIA positive Home visit nurse Study Period | 0 |
| Any perennial FEIA positive Home visit other health care Baseline Period | 0 |
| Any perennial FEIA positive Home visit other health care Study Period | 1 |
| Any perennial FEIA positive Telephone call physician Baseline Period | 19 |
| Any perennial FEIA positive Telephone call physician Study Period | 21 |
| Any perennial FEIA positive Telephone call nurse Baseline Period | 16 |
| Any perennial FEIA positive Telephone call nurse Study Period | 11 |
| Any perennial FEIA positive Telephone call specialist Baseline Period | 40 |
| Any perennial FEIA positive Telephone call specialist Study Period | 39 |
| Any perennial FEIA positive Telephone call other physician/health care Baseline Period | 8 |
| Any perennial FEIA positive Telephone call other physician/health care Study Period | 12 |
| Any perennial FEIA positive Medical testing spirometry Baseline Period | 83 |
| Any perennial FEIA positive Medical testing spirometry Study Period | 48 |
| Any perennial FEIA positive Medical testing advanced pulmonary function test Baseline Period | 22 |
| Any perennial FEIA positive Medical testing advanced pulmonary function test Study Period | 5 |
| Any perennial FEIA positive Medical testing plain chest X-ray Baseline Period | 52 |
| Any perennial FEIA positive Medical testing plain chest X-ray Study Period | 29 |
| Any perennial FEIA positive Medical testing computed tomography Baseline Period | 22 |
| Any perennial FEIA positive Medical testing computed tomography Study Period | 15 |
| Any perennial FEIA positive Medical testing oxygen initiated Baseline Period | 16 |
| Any perennial FEIA positive Medical testing oxygen initiated Study Period | 8 |
| Black/African American Any health-related events Baseline Period | 47 |
| Black/African American Any health-related events Study Period | 40 |
| Black/African American Asthma health-related events Baseline Period | 47 |
| Black/African American Asthma health-related events Study Period | 40 |
| Black/African American Ambulance transport Baseline Period | 4 |
| Black/African American Ambulance transport Study Period | 3 |
| Black/African American Hospitalization intensive care Baseline Period | 4 |
| Black/African American Hospitalization intensive care Study Period | 0 |
| Black/African American Hospitalization coronary care Baseline Period | 1 |
| Black/African American Hospitalization coronary care Study Period | 2 |
| Black/African American Hospitalization general care Baseline Period | 16 |
| Black/African American Hospitalization general care Study Period | 8 |
| Black/African American Urgent care visit Baseline Period | 15 |
| Black/African American Urgent care visit Study Period | 11 |
| Black/African American Emergency room visit Baseline Period | 28 |
| Black/African American Emergency room visit Study Period | 16 |
| Black/African American Hospital admission or emergency department >24 hours Baseline Period | 18 |
| Black/African American Hospital admission or emergency department >24 hours Study Period | 10 |
| Black/African American Visit to specialist Baseline Period | 42 |
| Black/African American Visit to specialist Study Period | 34 |
| Black/African American Visit to primary health care physician Baseline Period | 25 |
| Black/African American Visit to primary health care physician Study Period | 17 |
| Black/African American Other health care visit Baseline Period | 8 |
| Black/African American Other health care visit Study Period | 9 |
| Black/African American Home visit physician Baseline Period | 0 |
| Black/African American Home visit physician Study Period | 0 |
| Black/African American Home visit nurse Baseline Period | 2 |
| Black/African American Home visit nurse Study Period | 0 |
| Black/African American Home visit other health care Baseline Period | 0 |
| Black/African American Home visit other health care Study Period | 1 |
| Black/African American Telephone call physician Baseline Period | 10 |
| Black/African American Telephone call physician Study Period | 13 |
| Black/African American Telephone call nurse Baseline Period | 9 |
| Black/African American Telephone call nurse Study Period | 4 |
| Black/African American Telephone call specialist Baseline Period | 17 |
| Black/African American Telephone call specialist Study Period | 12 |
| Black/African America Telephone call other physician/health care Baseline Period | 5 |
| Black/African American Telephone call other physician/health care Study Period | 7 |
| Black/African American Medical testing spirometry Baseline Period | 34 |
| Black/African American Medical testing spirometry Study Period | 24 |
| Black/African American Medical testing advanced pulmonary function test Baseline Period | 12 |
| Black/African American Medical testing advanced pulmonary function test Study Period | 2 |
| Black/African American Medical testing plain chest X-ray Baseline Period | 28 |
| Black/African American Medical testing plain chest X-ray Study Period | 16 |
| Black/African American Medical testing computed tomography Baseline Period | 9 |
| Black/African American Medical testing computed tomography Study Period | 7 |
| Black/African American Medical testing oxygen initiated Baseline Period | 9 |
| Black/African American Medical testing oxygen initiated Study Period | 3 |
| Adolescents Any health-related events Baseline Period | 12 |
| Adolescents Any health-related events Study Period | 7 |
| Adolescents Asthma health-related events Baseline Period | 12 |
| Adolescents Asthma health-related events Study Period | 7 |
| Adolescents Ambulance transport Baseline Period | 0 |
| Adolescents Ambulance transport Study Period | 0 |
| Adolescents Hospitalization intensive care Baseline Period | 2 |
| Adolescents Hospitalization intensive care Study Period | 1 |
| Adolescents Hospitalization coronary care Baseline Period | 0 |
| Adolescents Hospitalization coronary care Study Period | 0 |
| Adolescents Hospitalization general care Baseline Period | 1 |
| Adolescents Hospitalization general care Study Period | 1 |
| Adolescents Urgent care visit Baseline Period | 3 |
| Adolescents Urgent care visit Study Period | 1 |
| Adolescents Emergency room visit Baseline Period | 4 |
| Adolescents Emergency room visit Study Period | 1 |
| Adolescents Hospital admission or emergency department >24 hours Baseline Period | 3 |
| Adolescents Hospital admission or emergency department >24 hours Study Period | 1 |
| Adolescents Visit to specialist Baseline Period | 9 |
| Adolescents Visit to specialist Study Period | 6 |
| Adolescents Visit to primary health care physician Baseline Period | 7 |
| Adolescents Visit to primary health care physician Study Period | 1 |
| Adolescents Other health care visit Baseline Period | 0 |
| Adolescents Other health care visit Study Period | 0 |
| Adolescents Home visit physician Baseline Period | 0 |
| Adolescents Home visit physician Study Period | 0 |
| Adolescents Home visit nurse Baseline Period | 0 |
| Adolescents Home visit nurse Study Period | 0 |
| Adolescents Home visit other health care Baseline Period | 0 |
| Adolescents Home visit other health care Study Period | 0 |
| Adolescents Telephone call physician Baseline Period | 0 |
| Adolescents Telephone call physician Study Period | 2 |
| Adolescents Telephone call nurse Baseline Period | 1 |
| Adolescents Telephone call nurse Study Period | 0 |
| Adolescents Telephone call specialist Baseline Period | 1 |
| Adolescents Telephone call specialist Study Period | 4 |
| Adolescents Telephone call other physician/health care Baseline Period | 0 |
| Adolescents Telephone call other physician/health care Study Period | 0 |
| Adolescents Medical testing spirometry Baseline Period | 10 |
| Adolescents Medical testing spirometry Study Period | 2 |
| Adolescents Medical testing advanced pulmonary function test Baseline Period | 3 |
| Adolescents Medical testing advanced pulmonary function test Study Period | 1 |
| Adolescents Medical testing plain chest X-ray Baseline Period | 2 |
| Adolescents Medical testing plain chest X-ray Study Period | 1 |
| Adolescents Medical testing computed tomography Baseline Period | 0 |
| Adolescents Medical testing computed tomography Study Period | 0 |
| Adolescents Medical testing oxygen initiated Baseline Period | 2 |
| Adolescents Medical testing oxygen initiated Study Period | 1 |
| Mild to moderate COPD Any health-related events Baseline Period | 42 |
| Mild to moderate COPD Any health-related events Study Period | 35 |
| Mild to moderate COPD Asthma health-related events Baseline Period | 42 |
| Mild to moderate COPD Asthma health-related events Study Period | 35 |
| Mild to moderate COPD Ambulance transport Baseline Period | 1 |
| Mild to moderate COPD Ambulance transport Study Period | 2 |
| Mild to moderate COPD Hospitalization intensive care Baseline Period | 2 |
| Mild to moderate COPD Hospitalization intensive care Study Period | 0 |
| Mild to moderate COPD Hospitalization coronary care Baseline Period | 2 |
| Mild to moderate COPD Hospitalization coronary care Study Period | 2 |
| Mild to moderate COPD Hospitalization general care Baseline Period | 6 |
| Mild to moderate COPD Hospitalization general care Study Period | 8 |
| Mild to moderate COPD Urgent care visit Baseline Period | 15 |
| Mild to moderate COPD Urgent care visit Study Period | 11 |
| Mild to moderate COPD Emergency room visit Baseline Period | 12 |
| Mild to moderate COPD Emergency room visit Study Period | 15 |
| Mild to moderate COPD Hospital admission or emergency department >24 hours Baseline Period | 6 |
| Mild to moderate COPD Hospital admission or emergency department >24 hours Study Period | 10 |
| Mild to moderate COPD Visit to specialist Baseline Period | 36 |
| Mild to moderate COPD Visit to specialist Study Period | 31 |
| Mild to moderate COPD Visit to primary health care physician Baseline Period | 17 |
| Mild to moderate COPD Visit to primary health care physician Study Period | 18 |
| Mild to moderate COPD Other health care visit Baseline Period | 9 |
| Mild to moderate COPD Other health care visit Study Period | 12 |
| Mild to moderate COPD Home visit physician Baseline Period | 0 |
| Mild to moderate COPD Home visit physician Study Period | 0 |
| Mild to moderate COPD Home visit nurse Baseline Period | 0 |
| Mild to moderate COPD Home visit nurse Study Period | 1 |
| Mild to moderate COPD Home visit other health care Baseline Period | 0 |
| Mild to moderate COPD Home visit other health care Study Period | 2 |
| Mild to moderate COPD Telephone call physician Baseline Period | 8 |
| Mild to moderate COPD Telephone call physician Study Period | 10 |
| Mild to moderate COPD Telephone call nurse Baseline Period | 2 |
| Mild to moderate COPD Telephone call nurse Study Period | 6 |
| Mild to moderate COPD Telephone call specialist Baseline Period | 8 |
| Mild to moderate COPD Telephone call specialist Study Period | 12 |
| Mild to moderate COPD Telephone call other physician/health care Baseline Period | 2 |
| Mild to moderate COPD Telephone call other physician/health care Study Period | 9 |
| Mild to moderate COPD Medical testing spirometry Baseline Period | 21 |
| Mild to moderate COPD Medical testing spirometry Study Period | 17 |
| Mild to moderate COPD Medical testing advanced pulmonary function test Baseline Period | 7 |
| Mild to moderate COPD Medical testing advanced pulmonary function test Study Period | 2 |
| Mild to moderate COPD Medical testing plain chest X-ray Baseline Period | 17 |
| Mild to moderate COPD Medical testing plain chest X-ray Study Period | 22 |
| Mild to moderate COPD Medical testing computed tomography Baseline Period | 13 |
| Mild to moderate COPD Medical testing computed tomography Study Period | 13 |
| Mild to moderate COPD Medical testing oxygen initiated Baseline Period | 7 |
| Mild to moderate COPD Medical testing oxygen initiated Study Period | 5 |
| Baseline Smokers Any health-related events Baseline Period | 58 |
| Baseline Smokers Any health-related events Study Period | 51 |
| Baseline Smokers Asthma health-related events Baseline Period | 58 |
| Baseline Smokers Asthma health-related events Study Period | 51 |
| Baseline Smokers Ambulance transport Baseline Period | 0 |
| Baseline Smokers Ambulance transport Study Period | 2 |
| Baseline Smokers Hospitalization intensive care Baseline Period | 5 |
| Baseline Smokers Hospitalization intensive care Study Period | 0 |
| Baseline Smokers Hospitalization coronary care Baseline Period | 2 |
| Baseline Smokers Hospitalization coronary care Study Period | 2 |
| Baseline Smokers Hospitalization general care Baseline Period | 7 |
| Baseline Smokers Hospitalization general care Study Period | 7 |
| Baseline Smokers Urgent care visit Baseline Period | 24 |
| Baseline Smokers Urgent care visit Study Period | 17 |
| Baseline Smokers Emergency room visit Baseline Period | 16 |
| Baseline Smokers Emergency room visit Study Period | 21 |
| Baseline Smokers Hospital admission or emergency department >24 hours Baseline Period | 9 |
| Baseline Smokers Hospital admission or emergency department >24 hours Study Period | 10 |
| Baseline Smokers Visit to specialist Baseline Period | 49 |
| Baseline Smokers Visit to specialist Study Period | 44 |
| Baseline Smokers Visit to primary health care physician Baseline Period | 24 |
| Baseline Smokers Visit to primary health care physician Study Period | 24 |
| Baseline Smokers Other health care visit Baseline Period | 7 |
| Baseline Smokers Other health care visit Study Period | 14 |
| Baseline Smokers Home visit physician Baseline Period | 0 |
| Baseline Smokers Home visit physician Study Period | 0 |
| Baseline Smokers Home visit nurse Baseline Period | 0 |
| Baseline Smokers Home visit nurse Study Period | 1 |
| Baseline Smokers Home visit other health care Baseline Period | 0 |
| Baseline Smokers Home visit other health care Study Period | 2 |
| Baseline Smokers Telephone call physician Baseline Period | 13 |
| Baseline Smokers Telephone call physician Study Period | 17 |
| Baseline Smokers Telephone call nurse Baseline Period | 9 |
| Baseline Smokers Telephone call nurse Study Period | 9 |
| Baseline Smokers Telephone call specialist Baseline Period | 19 |
| Baseline Smokers Telephone call specialist Study Period | 21 |
| Baseline Smokers Telephone call other physician/health care Baseline Period | 2 |
| Baseline Smokers Telephone call other physician/health care Study Period | 9 |
| Baseline Smokers Medical testing spirometry Baseline Period | 26 |
| Baseline Smokers Medical testing spirometry Study Period | 24 |
| Baseline Smokers Medical testing advanced pulmonary function test Baseline Period | 6 |
| Baseline Smokers Medical testing advanced pulmonary function test Study Period | 2 |
| Baseline Smokers Medical testing plain chest X-ray Baseline Period | 25 |
| Baseline Smokers Medical testing plain chest X-ray Study Period | 27 |
| Baseline Smokers Medical testing computed tomography Baseline Period | 18 |
| Baseline Smokers Medical testing computed tomography Study Period | 19 |
| Baseline Smokers Medical testing oxygen initiated Baseline Period | 6 |
| Baseline Smokers Medical testing oxygen initiated Study Period | 4 |
Duration of asthma-related hospitalization in 12-month period before \[baseline period (BP)\] and after initiation of tezepelumab \[up to study Week 52 = study period (SP)\] was assessed in following subgroups of participants: BEC≥300 cells/µL; BEC\<300 cells/µL; With clinically-relevant allergy to perennial aeroallergen; Without clinically-relevant allergy to perennial aeroallergen; Participants who identify as Black/African American; Adolescents (12-17 years); Comorbid diagnosis of mild to moderate COPD; Significant smoking history (≥10 pack-years of smoking).
| Crude Rate (days per year) | Tezepelumab |
|---|---|
| Baseline BEC: <300, hospitalization Study Period | 6.5463 |
| Baseline BEC: <300, hospitalization Baseline Period | 4.9057 |
| Baseline BEC: <300, hospitalization general care Study Period | 6.6300 |
| Baseline BEC: <300, hospitalization general care Baseline Period | 3.2970 |
| Baseline BEC ≥300, hospitalization Study Period | 2.7070 |
| Baseline BEC ≥300, hospitalization Baseline Period | 3.5506 |
| Baseline BEC ≥300, hospitalization general care Study Period | 2.6136 |
| Baseline BEC ≥300, hospitalization general care Baseline Period | 3.2110 |
| All perennial fluorescent enzyme immunoassay (FEIA) negative, hospitalization Study Period | 5.6316 |
| All perennial FEIA negative, hospitalization Baseline Period | 2.7594 |
| All perennial FEIA negative, hospitalization general care Study Period | 5.6316 |
| All perennial FEIA negative, hospitalization general care Baseline Period | 2.1323 |
| Any perennial FEIA positive, hospitalization Study Period | 5.8273 |
| Any perennial FEIA positive, hospitalization Baseline Period | 4.8863 |
| Any perennial FEIA positive, hospitalization intensive care Study Period | 3.4928 |
| Any perennial FEIA positive, hospitalization intensive care Baseline Period | 5.4631 |
| Any perennial FEIA positive, hospitalization general care Study Period | 6.5206 |
| Any perennial FEIA positive, hospitalization general care Baseline Period | 3.8256 |
| Baseline BEC <300 & with all perennial FEIA negative, hospitalization Study Period | 5.9877 |
| Baseline BEC <300 & with all perennial FEIA negative, hospitalization Baseline Period | 3.2110 |
| Baseline BEC <300 & with all perennial FEIA negative, hospitalization general care Study Period | 5.9877 |
| Baseline BEC <300 & with all perennial FEIA negative, hospitalization general care Baseline Period | 2.4082 |
| Baseline BEC ≥300 & with any perennial FEIA positive, hospitalization Study Period | 2.8760 |
| Baseline BEC ≥300 & with any perennial FEIA positive, hospitalization Baseline Period | 4.0137 |
| Black/African American, hospitalization Study Period | 5.5664 |
| Black/African American, hospitalization Baseline Period | 3.6006 |
| Black/African American, hospitalization general care Study Period | 5.9368 |
| Black/African American, hospitalization general care Baseline Period | 2.8849 |
| Mild to moderate COPD, hospitalization Study Period | 6.6060 |
| Mild to moderate COPD, hospitalization Baseline Period | 6.7373 |
| Mild to moderate COPD, hospitalization general care Study Period | 7.3133 |
| Mild to moderate COPD, hospitalization general care Baseline Period | 4.1810 |
| Baseline smokers, hospitalization Study Period | 9.2988 |
| Baseline smokers, hospitalization Baseline Period | 3.4117 |
| Baseline smokers, hospitalization general care Study Period | 10.5870 |
| Baseline smokers, hospitalization general care Baseline Period | 1.5768 |
| Baseline BEC <300 & with any perennial FEIA positive, hospitalization Study Period | 7.1639 |
| Baseline BEC <300 & with any perennial FEIA positive, hospitalization Baseline Period | 5.5575 |
| Baseline BEC <300 & with any perennial FEIA positive, hospitalization general care Study Period | 7.4268 |
| Baseline BEC <300 & with any perennial FEIA positive, hospitalization general care Baseline Period | 3.7908 |
The safety and tolerability of tezepelumab were assessed. Data for adverse events on-treatment period have been presented.
| Participants | Tezepelumab |
|---|---|
| Any SAE | 28 |
| Any SAE with outcome of death | 1 |
| Any AE leading to study intervention discontinuation | 6 |
Collected over Up to Week 52. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Tezepelumab | 2/286 (0.7%) | 31/286 (10.8%) | 4/286 (1.4%) |
| Event | Tezepelumab |
|---|---|
| AsthmaRespiratory, thoracic and mediastinal disorders | 6/286 |
| PneumoniaInfections and infestations | 4/286 |
| Pneumonia bacterialInfections and infestations | 3/286 |
| Non-cardiac chest painGeneral disorders | 2/286 |
| Atypical pneumoniaInfections and infestations | 1/286 |
| COVID-19Infections and infestations | 1/286 |
| COVID-19 pneumoniaInfections and infestations | 1/286 |
| Pneumonia viralInfections and infestations | 1/286 |
| Postoperative wound infectionInfections and infestations | 1/286 |
| Respiratory syncytial virus infectionInfections and infestations | 1/286 |
| Event | Tezepelumab |
|---|---|
| NeuralgiaNervous system disorders | 1/286 |
| SyncopeNervous system disorders | 1/286 |
| NauseaGastrointestinal disorders | 1/286 |
| AlopeciaSkin and subcutaneous tissue disorders | 1/286 |
| Rash erythematousSkin and subcutaneous tissue disorders | 1/286 |
| Ligament sprainInjury, poisoning and procedural complications | 1/286 |
| Procedural painInjury, poisoning and procedural complications | 1/286 |
| Intervertebral disc degenerationMusculoskeletal and connective tissue disorders | 1/286 |
| Muscle spasmsMusculoskeletal and connective tissue disorders | 1/286 |
| Muscle twitchingMusculoskeletal and connective tissue disorders | 1/286 |
Full analysis set (FAS) included all enrolled subjects who received at least 1 dose of tezepelumab, irrespective of their protocol adherence and continued participation in the study.
| Age, Continuous(years) | Tezepelumab |
|---|---|
| Mean | 52.9 ± 16.2 |
| Sex: Female, Male(Participants) | Tezepelumab |
|---|---|
| Female | 186 |
| Male | 100 |
| Ethnicity (NIH/OMB)(Participants) | Tezepelumab |
|---|---|
| Hispanic or Latino | 27 |
| Not Hispanic or Latino | 259 |
| Unknown or Not Reported | 0 |
| Race/Ethnicity, Customized(Participants) | Tezepelumab |
|---|---|
| White | 204 |
| Black or African American | 63 |
| Asian | 8 |
| American Indian or Alaska Native | 4 |
| Multiple | 0 |
| Not reported | 2 |
| Other | 5 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.
Supporting information: Study protocol, Statistical analysis plan
Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Access criteria: When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool. Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com
Ran from Apr 2022 to primary completion in Oct 2025, 41 months.
Results were first posted in Jul 2026, 9 months after primary completion.
Of 66 industry-sponsored phase 4 interventional studies under Asthma, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 33. This study's 41 months is above that.
Counting every sponsor, half of 156 studies reached it within 24 months; a quarter within 11 and three quarters within 37.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tezepelumab